Janux Therapeutics, Inc.
JANXNasdaqCIK 1817713HealthcareFiscal year ends Dec 31
Reports and events: 93 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0616:18 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-338078 |
| 2026-08-0616:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337977 |
| 2026-06-2316:05 ET | 8-K | 8.01 Other events | 0001193125-26-279428 |
| 2026-06-1216:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-269387 |
| 2026-05-0716:33 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-212146 |
| 2026-05-0716:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211964 |
| 2026-04-2817:02 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-187641 |
| 2026-04-2816:15 ET | DEF 14A | Proxy statementPeriod 2026-06-11 | 0001193125-26-187095 |
| 2026-02-2616:32 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-076918 |
| 2026-02-2616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076627 |
| 2026-01-2216:30 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-019520 |
| 2025-11-0616:39 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269799 |
| 2025-11-0616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269518 |
| 2025-09-1917:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-209259 |
| 2025-08-0716:22 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-105069 |
| 2025-08-0716:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-105010 |
| 2025-06-1316:35 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-086284 |
| 2025-05-0816:30 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-067083 |
| 2025-05-0816:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066969 |
| 2025-04-2516:39 ET | DEF 14A | Proxy statementPeriod 2025-04-25 | 0000950170-25-058806 |
| 2025-03-1016:33 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001415889-25-007529 |
| 2025-02-2716:53 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-029177 |
| 2025-02-2716:49 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-029165 |
| 2024-12-0516:32 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-271578 |
| 2024-12-0217:10 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-132302 |
| 2024-11-0817:58 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-116001 |
| 2024-11-0616:23 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122370 |
| 2024-11-0616:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122279 |
| 2024-10-2517:28 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-111544 |
| 2024-10-2216:17 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-110569 |
| 2024-10-2216:16 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-110567 |
| 2024-09-1621:41 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-100347 |
| 2024-09-1621:35 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-100346 |
| 2024-08-0916:09 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-24-000668 |
| 2024-08-0716:28 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-092857 |
| 2024-08-0716:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-092830 |
| 2024-07-2217:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-085321 |
| 2024-06-2816:12 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-079059 |
| 2024-06-0519:28 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-068766 |
| 2024-05-0820:14 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-054966 |
| 2024-05-0820:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-054950 |
| 2024-04-2916:16 ET | DEF 14A | Proxy statementPeriod 2024-06-26 | 0000950170-24-049873 |
| 2024-03-0816:23 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-028659 |
| 2024-03-0816:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-028647 |
| 2024-03-0618:54 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-031587 |
| 2024-03-0420:07 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-030638 |
| 2024-02-2917:11 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-023257 |
| 2024-02-2817:15 ET | 8-K | 8.01 Other events | 0000950170-24-022266 |
| 2024-02-2717:23 ET | 8-K | 8.01 Other events | 0000950170-24-021425 |
| 2024-02-2616:23 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-020183 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.